Please login to the form below

Not currently logged in

Excellence in Engagement through Digital Channels

Sponsored by

Back to Results


The Heart Failure Data Map: Demonstrating the Need for Action

by Novartis
with support from M&F Health

Summary of work

M&F Health developed the Heart Failure Data Map as part of Novartis’ Fighting Failure campaign to demonstrate the impact of the condition to national and local stakeholders, with a view to supporting the consideration of steps that can be taken to improve heart failure service provision and care, and as a result outcomes and quality of life for patients.
Historic estimates of the total heart failure population in the UK have long been considered an under representation of the true number of people affected by the condition, and as a result, it has remained poorly recognised and under prioritised.
However, in 2018, a landmark new study was published by Conrad et al. that estimated the true prevalence of heart failure to be nearly 1 million in the UK, which helped to shine a light on the urgent need for action in this area.
As such, the Heart Failure Data Map was developed to set out the impact of heart failure across several key data categories, to provide a platform to engage with Parliamentarians, national and local-level policymakers and commissioners to raise awareness of the condition and encourage action to reduce the impact it has on both patients and the NHS.

Judges' comments

The judges liked the Heart Failure Data Map for the use of data to drive this campaign and the evidence-based approach used. It was a strongly focussed campaign, addressing a major health issue which has not been appropriately recognised by policy makers.


SMA: A Race Against Time - by Novartis Gene Therapies
with support from Havas Life Medicom

Highly commended

Break Over-Reliance - by AstraZeneca
with support from Real Chemistry


'Up for the Challenge' - by Galapagos/ Gilead
with support from Purple Agency

The Heart Failure Data Map: Demonstrating the Need for Action - by Novartis
with support from M&F Health

Myeloproliferative Neoplasms Virtual Speaker Training Program 2021 - by Novartis
with support from Langland

Key dates

Entry deadline 26 August 2022
Extended entry deadline 2 September 2022*
*additional fee applies
Judging Day 6 October 2022
Company/Team of the Year Interviews 21 October 2022
PMEA Event 23 November 2022